Fibroblast growth factor 19, a double-edged sword.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2017-01-01 Epub Date: 2017-07-06 DOI:10.2217/hep-2017-0008

Peter Lm Jansen

引用次数: 4

Abstract

The liver is specialized in handling bile salts. Bile salts are needed for bile formation and the digestion of fats in the intestine. It is this digestive function that makes bile salts cytotoxic. At concentrations in the millimolar range bile salts act as detergents and at lower concentrations they are proapoptotic, proinflammatory and cause necrosis [1] . Therefore, when during evolution changes in nutritional habits demanded the digestion of fats as a source of calories, bile salts with detergent properties were needed and mechanisms evolved to limit the toxicity of bile salts in the liver. The farnesoid X-receptor (FXR) and FGF19 play a critical role as protectors of the liver. The

Abstract Image

查看原文本刊更多论文

成纤维细胞生长因子19，一把双刃剑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.